Organization of ICB&DD
ICB&DD is organized in conjunction with the Chemistry Department and the core laboratories, facilities, and offices are located in the Chemistry Building. However, its operation and management are independent of the Chemistry Department. It is essential for this "Center of Excellence" that the Director of ICB&DD directly reports to the University Executive Committee, i.e., Provost, Vice President for Research, and Vice President for the Health Sciences Center. Dr. Ojima, Distinguished Professor of Chemistry, serves as the founding Director of the institute. ICB&DD has core Members, Project Members, Steering Committee Members, and Advisory Board Members. The activities of the Director and Members will be reviewed every 5 years. In addition, there is a Laboratory Director for Bioanalytical Instrumentation (a Ph.D. chemist) as well as a Laboratory Director for Combinatorial Chemistry and Synthesis (a Ph.D. chemist) and his/her Technical Support Specialist (a B.S./M.S. chemist). Both Laboratory Directors of the ICB&DD facilities report to the Director of the Institute. ICB&DD will take the "Team Project" approach to attack major biomedical problems. Accordingly, Project Members and Advisory Board Members will be invited to participate in particular projects which may lead to a dynamic change in membership, contingent on the status of projects and necessary expertise. The current members of ICB&DD are as follows:
Director: Iwao Ojima (Distinguished Professor, Chemistry)
Steering Committee Members: James Bliska (Molecular Genomics and Microbiology), Todd Miller (Physiology and Biophysics), Roy Steigbigel (SOM), Stanley Zucker (SOM/VA), Carl Anderson (BNL), Maria Ryan (Oral Biology and Pathology), Basil Rigas (Department of Preventive Medicine/ Pharmacological Sciences), Peter Tonge (Chemistry), Daniel Raleigh (Chemistry), Carlos Simmerling (Chemistry) and Wadie Bahou (SOM).
Members: Jeffrey Pessin (Chair, Pharmacological Sciences), Nicole Sampson (Chemistry,) Daniel Raleigh (Chemistry), Peter Tonge (Chemistry), Carlos Simmerling (Chemistry), Francis Johnson (Pharmacological Sciences/Chemistry), Carlos de la Santos (Pharmacological Sciences), Robert Haltiwanger (Biochemistry and Cell Biology), Rob Rizzo (Applied Mathematics and Statistics), Orlando Scharer (Pharmacology/Chemistry).
Project Members: Kathlyn Parker (Chemistry), Dale Drueckhammer (Chemistry), Jin Wang (Chemistry), Elizabeth Boon (Chemistry), Isaac Carrico (Chemistry), Howard Crawford (Pharmacology), Ralph Bernacki (Roswell Park Cancer Institute), Giovanni Appendino (Università del Piemonte Orientale Italy), Teruo Kirikae (International Medical Center of Japan), Philippe Rasoanaivo (Institut Malgache de Recherches Appliquées), Eduardo Muñoz (University of Córdoba),David Green (Applied Mathematics & Statistics), Jian Cao (SOM, Oncology),Galina Botchkina (SOM, Surgical Oncology), Wei-Xing Zong (Molecular Genetics & Microbiology), Richard Lin (SOM, Hematology), Takushi Kaneko (Chemistry/TB Alliance Inc.), Lee Arnold (Chemistry/DiscoverElucidations, LLC).
Advisory Board Members: Susan Horwitz (A. Einstein Coll. Med.), Richard Clark (Biomedical Engineering), John Kovach (Long Island Cancer Center), Wendy Cornnel (Director, Molecular Systems Modeling Group, Merck and Co), James Staros (Biochemistry and Cell Biology, Dean of CAS), John Piwinski (Schering-Plough), Robert Volkmann (Pfizer), Adrian Whitty (Biogen), William Murray (Johnson Pharmaceutical Research Institute), Ezio Bombardelli (Indena, SpA), Arlindo Castelhano (OSI Pharmaceuticals), Lorne Taichman (Oral Biology and Pathology).